Phase separation of an IgG1 antibody solution under a low ionic strength condition.
OBJECTIVE
Phase separation of monoclonal antibody A (MAb A) solution and its relation to protein self-association are studied.


METHODS
A phase diagram of MAb A and its dependence on ionic strength and pH were investigated. The protein self-associations were characterized by dynamic light scattering (DLS), analytical ultracentrifugation analysis (AUC) and viscosity measurement.


RESULTS
MAb A solution with a clear appearance in an isotonic ionic strength condition turned opalescent in a low ionic strength condition, followed by liquid-liquid phase separation (LLPS) into light and heavy phases. The protein concentrations of the two phases were dependent on the ionic strength and pH. The two phases became reversibly miscible when the ionic strength or temperature was increased. DLS and AUC showed that MAb A under a low ionic strength condition self-associates at a protein concentration above the critical concentration of 16.5 mg/mL. The viscosity of the heavy phase was high and dependent on the shear rate. These results indicate that attractive protein-protein interaction in the heavy phase induces LLPS.


CONCLUSIONS
LLPS was induced in MAb A solution in a low ionic strength condition due to reversible protein self-association mediated mainly by attractive electrostatic interaction among the MAb A molecules in the heavy phase.
Nishi
Hirotaka
H
Formulation Technology Research Laboratories, Daiichi Sankyo Co., Ltd., 1-12-1 Shinomiya, Hiratsuka, Kanagawa, 254-0014, Japan.
Miyajima
Makoto
M
Nakagami
Hiroaki
H
Noda
Masanori
M
Uchiyama
Susumu
S
Fukui
Kiichi
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry*; D045744:Cell Line, Tumor; D004797:Enzyme-Linked Immunosorbent Assay; D006863:Hydrogen-Ion Concentration; D007074:Immunoglobulin G / Q000737:chemistry*; D051379:Mice; D009994:Osmolar Concentration; D019999:Pharmaceutical Solutions / Q000737:chemistry*; D044367:Phase Transition; D014783:Viscosity
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D019999:Pharmaceutical Solutions
Acta Crystallogr D Biol Crystallogr. 1994 Jul 1;50(Pt 4):361-5
15299385
J Pharm Sci. 2007 Dec;96(12):3181-95
17588261
Methods Enzymol. 1997;276:100-110
27799086
Biophys J. 2007 Jan 1;92(1):234-44
17028129
Biochim Biophys Acta. 2007 Jan;1774(1):146-53
17142116
Int J Pharm. 2008 Jun 24;358(1-2):1-15
18485634
J Pharm Sci. 2009 Sep;98(9):3043-57
18823016
J Pharm Sci. 2005 Jun;94(6):1161-8
15858846
Pharm Res. 2009 Dec;26(12):2607-18
19795191
Proc Natl Acad Sci U S A. 1987 Oct;84(20):7079-83
3478681
J Pharm Sci. 2010 Jan;99(1):82-93
19475558
J Mol Biol. 2000 Jan 14;295(2):213-24
10623521
J Pharm Sci. 2009 Sep;98(9):3108-16
19025898
J Pharm Sci. 2006 Sep;95(9):1967-83
16847932
Biotechnol Bioeng. 2009 Mar 1;102(4):1141-51
19031425
J Pharm Sci. 2008 Oct;97(10):4219-27
18240303
Biotechnol Bioeng. 2006 Dec 5;95(5):911-8
16804945
Biophys J. 2000 Mar;78(3):1606-19
10692345
J Pharm Sci. 2010 Mar;99(3):1152-68
19705420
Proteomics. 2006 Jul;6(13):3958-60
16718732
Science. 1977 Sep 2;197(4307):1010-2
887936
Biochemistry. 2007 Jul 17;46(28):8373-8
17590018
Biol Pharm Bull. 2002 Dec;25(12):1537-45
12499636
Nature. 2004 Nov 25;432(7016):492-5
15565151
Methods Enzymol. 1998;295:127-49
9750217
Pharm Res. 1997 Oct;14(10):1472-8
9358564
Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-77
8124728
Int Rev Cytol. 2000;192:171-87
10553279
Pharm Res. 2004 Jul;21(7):1087-93
15290846
Anal Biochem. 2007 Aug 15;367(2):225-37
17548043
Biophys J. 2008 Jan 15;94(2):570-83
18160663
AAPS J. 2006 Sep 22;8(3):E580-9
17025276
Mol Immunol. 2004 Nov;41(12):1211-5
15482856
Biophys J. 2003 Jan;84(1):523-32
12524304
Pharm Res. 2004 Jun;21(6):897-903
15212151
J Pharm Sci. 2005 Sep;94(9):1928-40
16052543
Mol Immunol. 2009 Dec;47(2-3):357-64
19800690
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14165-70
12391331
Biophys J. 2007 Jul 15;93(2):610-9
17449660
J Pharm Sci. 2004 Jun;93(6):1390-402
15124199